METHANTHELINE BROMIDE Property

Melting point:

175-176°

Density 

1.3380 (rough estimate)

refractive index 

1.6200 (estimate)

storage temp. 

-20°C Freezer, Under inert atmosphere

solubility 

Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)

form 

Solid

color 

Dark Orange to Very Dark Orange

Safety

Toxicity

LD50 i.p. in mice: 76 mg/kg (Hambourger)

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

H332Harmful if inhaled

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P271Use only outdoors or in a well-ventilated area.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P304+P340IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.

P312Call a POISON CENTER or doctor/physician if you feel unwell.

P330Rinse mouth.

P501Dispose of contents/container to..…

METHANTHELINE BROMIDE Chemical Properties,Usage,Production

Uses

Ulcine is a strong muscarinic receptor blocking drug used in the treatment of overactive bladder syndrome, hypersalivation and hyperhidrosis.

Uses

METHANTHELINE BROMIDE is a strong muscarinic receptor blocking drug used in the treatment of overactive bladder syndrome, hypersalivation and hyperhidrosis.

Definition

ChEBI: Methantheline bromide is a member of xanthenes.

General Description

Methanthelinebromide, diethyl(2-hydroxyethyl)methylammonium bromidexanthene-9-carboxylate (Banthine Bromide), is awhite, slightly hygroscopic, crystalline salt that is solublein water to produce solutions with a pH of about 5.Aqueous solutions are not stable and hydrolyze in a fewdays. The bromide form is preferable to the very hygroscopicchloride.
Among the conditions for which methantheline bromideis indicated are gastritis, intestinal hypermotility, bladderirritability, cholinergic spasm, pancreatitis, hyperhidrosis,and peptic ulcer, all of which are manifestations ofparasympathotonia.

Clinical Use

Methantheline bromide, introduced in 1950, is a potent anticholinergicagent and acts at the nicotinic cholinergic receptors of thesympathetic and parasympathetic systems, as well as at themyoneural junction of the postganglionic cholinergic fibers.Like other quaternary ammonium drugs, methantheline bromideis absorbed incompletely from the GI tract.